Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions David Driscoll
NeurochemNRM.TOSELLFeb 23, 2006
He likes it, the only downside is that because the Japaneese market has risen 40% over the last year, it's a bit expensive right now. He suggests going to a different fund which is not so centered on the Japaneese market.
David DriscollUnknown
$17.60
Stock price when the opinion was issued
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
COMMENT
The name of the company was indistinct and this is the closest result in the data base. It is a biotech company focused on brain health. It acquired an AI company called Metro Mark. It is signing more and more deals with pharmaceutical companies for up-front and royalty payments.
biotechnologypharmaceutical
BUY
There has been a general selloff of biotech stocks. Still believe in this company.
Michael SmedleyOwned
biotechnologypharmaceutical
PAST TOP PICK
(A top pick Sept 9/03. Up100 %.) Still likes. The market opportunity is so big, would still buy at this price.
Peter HodsonOwned
biotechnologypharmaceutical
PAST TOP PICK
(A top pick Sept 9/03. Up 58%.) As a potential treatment for Alzheimer's. Good technology. Has some US financing which will get US investors interested.
Peter HodsonOwned
biotechnologypharmaceutical
TOP PICK
Into phase 3 trial. All cashed up. Will start to be getting attention.
Peter HodsonOwned
biotechnologypharmaceutical
BUY
